title: Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide.
abstract: Procainamide is a class I antiarrhythmic agent that undergoes active tubular secretion through the organic cation transport system, with approximately 50% of a dose excreted in the urine as unchanged drug. The remainder is metabolized to an active metabolite, n-acetyl procainamide (NAPA). Ofloxacin is a fluoroquinolone antibiotic that is excreted in the urine as unchanged drug via active tubular secretion and glomerular filtration. To test the hypothesis that ofloxacin may interfere with the renal elimination of procainamide, 9 healthy volunteers were randomly assigned to receive 1 g of oral procainamide as a single dose with or without pretreatment with 400 mg of ofloxacin twice a day for 5 doses. Blood and urine samples were obtained and pharmacokinetic parameters for procainamide were determined for each treatment period. Standard 12-lead and signal-averaged electrocardiographic recordings were used for pharmacodynamic analysis. The mean area under the concentration-time curve (AUC) and peak plasma concentration (Cmax; mug/mL) for procainamide increased by 27% and 21%, respectively, and the plasma clearance for procainamide decreased by an average of 22% with coadministration of ofloxacin. Ofloxacin did not significantly influence the pharmacokinetics of NAPA, nor were pharmacodynamics of procainamide significantly affected by coadministration of ofloxacin. These results suggest that procainamide concentrations should be monitored closely when coadministered with ofloxacin.
authors.affiliation: University of North Carolina, Chapel Hill, USA.
authors.forename: D E
authors.initials: DE
authors.lastname: Martin
authors.forename: J
authors.initials: J
authors.lastname: Shen
authors.forename: J
authors.initials: J
authors.lastname: Griener
authors.forename: R
authors.initials: R
authors.lastname: Raasch
authors.forename: J H
authors.initials: JH
authors.lastname: Patterson
authors.forename: W
authors.initials: W
authors.lastname: Cascio
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000493:pharmacokinetics*; D000890:Anti-Infective Agents / Q000097:blood / Q000494:pharmacology*; D001667:Binding, Competitive; D001692:Biological Transport / Q000187:drug effects; D018592:Cross-Over Studies; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007684:Kidney Tubules / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000097:blood / Q000494:pharmacology*; D011342:Procainamide / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000889:Anti-Arrhythmia Agents; D000890:Anti-Infective Agents; D015242:Ofloxacin; D011342:Procainamide